1. Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer 
David J. Stewart, MD, Maria I. Nunez, MD, Carmen Behrens, MD, Diane Liu, MS, Yan Heather Lin, PhD, J. Jack Lee, PhD, Jack Roth, MD, John Heymach, MD, PhD, Stephen G. Swisher, MD, Waun Ki Hong, MD, Ignacio Ivan Wistuba, MD 
Journal of Thoracic Oncology 
Volume 9, Issue 5, Pages (May 2014)
DOI: /JTO
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Microphotographs illustrating carbonic anhydrase IX (CAIX) immunohistochemistry expression in malignant cells of lung cancer tissue specimens (×40). A, Combined CAIX strong membrane and cytoplasmic expressions in a squamous cell carcinoma. B, Strong CAIX membrane expression in a squamous cell carcinoma. C, Moderate CAIX cytoplasmic expression in an adenocarcinoma. D, Lack of CAIX expression in a poorly differentiated adenocarcinoma.
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Kaplan-Meier curves for relapse and survival by nodal and membrane carbonic anhydrase IX (mCAIX) staining status (E/N: no. of events/no. of cases). A, Time to relapse: the 60-month probability of freedom from recurrence was (95% confidence interval [CI], 0.783, 0.957), (95% CI, 0.621–0.818), 0.70 (95% CI, 0.467, 1.0), and (95% CI, 0.213, 0.748) for N0/mCAIX negative (red), N0/mCAIX positive (blue), N1/mCAIX negative (green), and N1/mCAIX positive (black) patients, respectively. B, Overall survival: the 60-month probability of being alive was (95% CI, 0.647, 0.858), (95% CI, , 0.742), (95% CI, 0.506, 1.0), and (95% CI, 0.149, 0.497) for N0/mCAIX negative (red), N0/mCAIX positive (blue), N1/mCAIX negative (green), and N1/mCAIX positive (black) patients, respectively.
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions